Skip to main content

Safe Group ships several dozen ready-to-use surgical kits to two hospitals in Ukraine

Written by Customer Service on . Posted in Public Companies.

                                                                                                                                                                                                                                                                                                  

 

Safe Group ships several dozen ready-to-use surgical kits to two hospitals in Ukraine

 

  • Safe Group has responded positively to requests from several Ukrainian hospital surgical teams,
  • These complete kits (instruments and implants) are delivered sterile and intended for indications of traumatic spine surgery.
  • Medical teams in Ukraine are facing major logistical tensions, particularly in ensuring instrument sterilization.

 

   

 

 

Eragny-sur-Oise, France, March 25th, 2022 08h45 CET – Safe (FR0013467123 – ALSAF), a company specializing in the design, manufacturing and marketing of single-use technologies for spinal surgeries, delivering the safest treatment for spinal fractures urgently treated, announces today the shipment of several dozen complete ready-to-use surgical kits (implants and instruments) to two hospitals:

  • Dnipro Military Hospital (neurosurgery department, Dr. Igor Kurilets)
  • Kharkiv University Clinic (Trauma Department, Dr. Dimytro Petrenko)

Since the beginning of the conflict between Ukraine and Russia, Ukrainian hospitals are under stress and have to treat a large number of patients in emergency. Two hospitals were informed about the ready-to-use solutions offered by Safe Orthopaedics and made an explicit request for emergency delivery.

Dr. Igor Kurilets, Head of the Neurosurgery Department of Dnipro Military Hospital, asks: “…I am currently serving in the Ukrainian Army as a neurosurgeon at Dnipro Military Hospital. We now have many wounded soldiers and many of them have spinal injuries. To help them, we have to not only perform decompression surgeries, but also stabilize their spine (transpedicular stabilization). We have a C-arm here, but we don’t have instruments for stabilization and screws…”.

Dr. Dimytro Petrenko, Head of Orthopedics and Traumatology Department of Kharkiv University Hospital, asks: “On behalf of Kharkiv University Clinic and its Orthopedics and Traumatology Department, we ask you to help us provide a safe orthopedic solution dedicated to different types of emergency spine treatment. In a given war situation to support the military as well as the civilian population of Kharkiv. Your unique solution would greatly contribute to our success.”.

As a reminder, Safe Orthoapedics’ technologies come in the form of surgical kits including implants and pre-assembled single-use instruments delivered sterile.

Safe Orthopaedics, which is not distributed in Ukraine, has delivered about ten surgical kits per hospital, organized secure delivery through its Polish distributor and offers remote support and training services.

Pierre Dumouchel, CEO of Safe Group, said: “From a human point of view, we deplore this war situation and as soon as we received the requests for support from doctors Kurilets and Petrenko, our teams mobilized to respond. Our ready-to-use kits, unique solutions in this difficult context, have been shipped and delivered to Ukraine thanks to the support of our Polish distributor. Together, we remain mobilized to provide training for remote medical teams and proper patient care”.

About Safe Group
Safe Group is a French medical technology group that brings together Safe Orthopaedics, a pioneer in ready-to-use technologies for spine pathologies, and Safe Medical (formerly LCI Medical), a medical device subcontractor for orthopedic surgery. The group employs approximately 150 people.

Safe Orthopaedics develops and manufactures kits combining sterile implants and single-use instruments, available at any time to the surgeon. These technologies are part of a minimally invasive approach aimed at reducing the risks of contamination and infection, in the interest of the patient and with a positive impact on hospitalization times and costs.  Protected by 18 patent families, SteriSpineTM kits are CE marked and FDA approved. Safe Orthopaedics is headquartered in the Paris region (95610 Eragny-sur-Oise) and has subsidiaries in the United Kingdom, Germany, the United States and the Lyon region (Fleurieux-sur-l’Arbresle).

For more information: www.safeorthopaedics.com

Safe Medical produces implantable medical devices and ready-to-use instruments. It has an innovation center and two production sites in France (Fleurieux-sur-l’Arbresle, 69210) and in Tunisia, offering numerous industrial services: design, industrialization, machining, finishing and sterile packaging. Supported by the French stimulus plan in 2020, the company invests in additive printing and will be operational in 2022 on this new technology.

For more information: www.safemedical.fr

Contacts 

Safe Group                                                                                                           

François-Henri Reynaud                 
Chief Financial and Administrative Officer                            
Tél. : +33 (0)1 34 21 50 00                                
investors@safeorthopaedics.com                            

Press Relations
Ulysse Communication
Pierre-Louis Germain / +33 (0)6 64 79 97 51 / plgermain@ulysse-communication.com  
Bruno Arabian / +33 (0)6 87 88 47 26 / barabian@ulysse-communication.com  

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.